Anzeige
Mehr »
Montag, 06.07.2026 - Börsentäglich über 12.000 News
8,8-Mio.-Nanocap direkt neben Europas Lithium-Giganten - jetzt steigt die Spannung
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QB6B | ISIN: US26818M1080 | Ticker-Symbol:
NASDAQ
06.07.26 | 20:44
22,680 US-Dollar
-1,69 % -0,390
1-Jahres-Chart
DYNE THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
DYNE THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur DYNE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
26.06.Dyne Therapeutics stock initiated at buy by TD Cowen on platform4
DYNE THERAPEUTICS Aktie jetzt für 0€ handeln
22.06.Dyne Therapeutics appoints Barry Greene to board of directors1
22.06.Dyne Therapeutics, Inc.: Dyne Therapeutics Appoints Barry Greene to Board of Directors1
18.06.Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)1
17.06.Dyne Pops on Changing Loan Facility-
17.06.Dyne Therapeutics expands debt facility with Hercules Capital to $400M9
17.06.Dyne Therapeutics erweitert Kreditfazilität auf 400 Millionen US-Dollar1
17.06.Dyne Therapeutics amends loan facility, secures $50 million3
17.06.Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.707- Up to $125 million in additional borrowing capacity provides further strategic flexibility - - $50 million of additional capacity funded at amendment closing - WALTHAM, Mass., June 17, 2026 (GLOBE...
► Artikel lesen
17.06.Dyne Therapeutics, Inc. - 8-K, Current Report1
03.06.Dyne completes enrollment in DM1 therapy trial expansion cohort3
03.06.Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1)277- Registrational expansion cohort enrolled 71 participants; topline data planned for Q1 2027 - WALTHAM, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage...
► Artikel lesen
03.06.Dyne Therapeutics, Inc. - 8-K, Current Report1
26.05.Dyne submits biologics license application for DMD treatment2
26.05.Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)476- Submission for Accelerated Approval based on dystrophin as a surrogate endpoint - - In the registrational expansion cohort of the DELIVER trial, treatment with z-rostudirsen resulted in a robust...
► Artikel lesen
20.05.Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)3
20.05.Dyne spikes as late-stage trial for Duchenne therapy gets underway3
20.05.Dyne Therapeutics startet entscheidende Phase-3-Studie für DMD-Medikament3
20.05.Dyne Therapeutics launches phase 3 trial for DMD treatment5
20.05.Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval360- 72-week trial will enroll approximately 90 participants; first site now open for enrollment - - Primary endpoint is rise from floor (RFF) velocity with multiple secondary endpoints to assess muscle...
► Artikel lesen
Weiter >>
66 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1